BICXOTCServices-Specialty Outpatient Facilities, NECFiscal year ends December 31

BioCorRx Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.25+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $7.30M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q2 FY2015 Ended Jun 30, 2015	Sep 22, 2015	During market hours	–	–	–

Press releases

Announcements BioCorRx filed with the SEC

Mar 11, 2025, 1:43 PM ET
BioCorRx Pharmaceuticals Inc. announces that it has acquired LUCEMYRA ® (lofexidine), an FDA-Approved Opioid Withdrawal Medication, from USWM, LLC
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K

Where these numbers come from

Parsed from the XBRL in BioCorRx's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Apr 16, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BICX.

Revenue growth10301.1% · median -29.6%

Operating margin-614.8% · median -271.4%

Net margin-396.5% · median -289.3%

Company	Revenue	Growth
EHSI	$3.73M	–
HLYK	$1.37M	-46.7%
ATPC	$1.15M	-20.3%
BICX	$797.24K	+10301.1%
BRTX	$357.87K	-8.5%
MGRX	$315.23K	-38.9%

Company

Exchange: OTC
Industry: Services-Specialty Outpatient Facilities, NEC
Fiscal year ends: December 31
Employees: 3
Auditor: M&K CPAS, PLLC
SEC CIK: 1443863

Advertisement
300 × 250